The Discovery of Ledipasvir (GS-5885): The Potent Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimen Harvoni

The advent of direct-acting antiviral agents (DAAs) has revolutionized the treatment and cure of chronic hepatitis C virus (HCV) infection. Herein is described the discovery of ledipasvir (LDV), an orally available HCV nonstructural protein 5A inhibitor with picomolar antiviral potency and a long ph...

Ausführliche Beschreibung

Bibliographische Detailangaben

1. Verfasser:	Link, John O.
Format:	Buchkapitel
Sprache:	eng
Schlagworte:	Direct-acting antiviral GS-5885 Harvoni HCV LDV/SOF Ledipasvir NS5A inhibitor NS5B nucleotide inhibitor Single-tablet regimen
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!